Tripep’s rights offering oversubscribed

NewsGuard 100/100 Score

The preliminary result from Tripep’s (STO:TPEP) rights offering shows that it has been oversubscribed with significant marginal (approximately 150%). Through the offering Tripep will receive approximately 17.8 MSEK before emission costs. The final outcome of the emission will be presented around the 30th of December 2009.

Those who have subscribed for shares without rights will be allotted shares according to the principles outlined in the prospectus. Notice of allotments will be around the 30th of December 2009 and only given to those who receive shares.

After the emission the number of shares in Tripep will increase by 35,575,314 up to 71,150,628. Tripep’s share capital increases with 1,067,259.42 SEK to 2,134,518.84 SEK.

”The interest in the present offering has exceeded expectations. It is delightful that both our present shareholders as well as new potential shareholders have shown us such high interest. The money from the emission makes it possible for us to develop our projects according to plan during 2010 and it is with great excitement we look ahead for an eventful new year. We wish all our shareholders a Merry Christmas and a Happy New Year”, says Tripep’s CEO Anders Vahlne.

Source:

http://www.cisionwire.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.